Edwards Lifesciences Corporation EW
Verdict: Sell. Fair value $73.07 against a price of $84.17 on 6 Jan 2026, 13% below the price.
In plain words
The case for: Narrow competitive moat provides durability. Market leadership enables pricing power. Industry tailwinds with growing market.
The case against: Intense competitive pressure could compress margins. In 2024, Net Income was $4.17B while Operating Cash Flow was only $0.54B. This results in an.... The accruals ratio for 2024 is calculated at +0.278, which is nearly three times the red flag....
Main risks
- Severe Free Cash Flow Deterioration: Annual FCF has collapsed from $1.40B in 2021 to $0.26B in 2024. The TTM FCF margin of 13.6% is less than half the ~27% margin from 2021, indicating a significant decline in cash-generating ability.
- Anomalous 2024 Net Income: The reported 2024 Net Income of $4.17B implies a 76.7% net margin, which is unsustainable and likely driven by a large non-recurring gain. This masks weaker underlying operational trends suggested by FCF and proxy EBIT.
- Negative Incremental Returns on Capital: The estimated 3-year ROIIC is -49.2%, suggesting that capital invested over the last three years has destroyed value. This is a major red flag regarding capital allocation effectiveness and aligns with the declining FCF.
- In 2024, Net Income was $4.17B while Operating Cash Flow was only $0.54B. This results in an...
- The accruals ratio for 2024 is calculated at +0.278, which is nearly three times the red flag...
- Intense competitive environment